B7-H3^−/− splenocytes retain a GVL effect. (A) BALB/c mice were lethally irradiated and infused with 10⁷ BALB/c T-cell-depleted BM. Mice were infused with phosphate-buffered saline (PBS) (no DLI) or either 30 × 10⁶ B6-WT or B7-H3^−/− splenocytes (Spl) (DLI; day 50). Three days later, the mice were infused with 10⁶ A20^luc tumor cells (n = 10 per group). One experiment was performed. No DLI vs B6-WT DLI, P = .0092; no DLI vs B7H3^−/− DLI, P = .0014. (B) Mice were monitored for clinical scores that were not significant on day 30 or day 75 (n = 10 per group). One experiment was performed. No DLI vs WT or B7H3 ^−/− DLI, P ≤ .01. (C) BALB/c mice were lethally irradiated and infused with 10⁷ B6 NTCD BM. Mice were then infused with 25 × 10⁶ splenocytes (DLI; day 28) from B6-WT or B6-B7-H3^−/− donors (n = 8 per group; 1 experiment was performed) or PBS (no DLI) as a control. Three days later, the mice were infused with 4 × 10⁶ A20^luc tumor cells (day 31). Survival after tumor infusion is shown (n = 7-8 mice per group; 1 experiment was performed). For PBS vs B6-WT DLI or B6-B7-H3^−/− DLI, P < .01.